ELDN Stock Forecast: Eledon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.78
−6.32% on the day

The median 12-month analyst price target for Eledon Pharmaceuticals, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$150.3M
Ticker Nerd rank
29/ 100
Median analyst target
$8.00
Analysts covering
6
Revenue$0.0
Operating income−$22.9M
Net income−$31.6M
Free cash flow−$22.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.8%
1M
−21.1%
YTD
+17.9%
1Y
+28.1%
From 52W high
−57.7%
From 52W low
+28.1%
$1.39
$4.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Eledon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
29/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
49
Growth
49
Momentum
42
Revisions
42
Accruals
42
Quality
34
Issuance
34
Value
29

Volatility (49): The share price has been relatively steady.

Value (29): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ELDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ELDNHigh $12.00Median $8.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$7.00
Low
$8.00
Median
$12.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026Rodman & RenshawInitiatesBuy$12
18 Nov 2025GuggenheimMaintainsBuy$9.00 → $8.00
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
25 July 2025Craig-HallumInitiatesBuy—
18 June 2025HC Wainwright & Co.AssumesBuy$9.00
20 Nov 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
10 May 2024HC Wainwright & Co.ReiteratesBuy—
7 May 2024HC Wainwright & Co.MaintainsBuy—
22 Mar 2024HC Wainwright & Co.ReiteratesBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
24 Oct 2023HC Wainwright & Co.MaintainsBuy—
27 Sept 2023Noble Capital MarketsInitiatesOutperform—
22 Aug 2023Cantor FitzgeraldReiteratesOverweight—
26 May 2023HC Wainwright & Co.ReiteratesBuy—
1 June 2022SVB LeerinkMaintainsOutperform—
24 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 Apr 2021SVB LeerinkMaintainsOutperform—
23 Mar 2021Cantor FitzgeraldInitiatesOverweight—
8 Feb 2021SVB LeerinkInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELDN.

Market Radar

This page is one stock. Monday covers all of them.

ELDN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ELDN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Eledon Pharmaceuticals, Inc. returned +28.1% against +6.9% for the S&P 500, dividends included.

ELDN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26ELDNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−105.7%

Higher than 13% of US stocks

Return on assets
−46.1%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eledon Pharmaceuticals, Inc. has a market value of $150.3M and an enterprise value of $81.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$98.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$73.9M.

  • Shares outstanding: 80.9M.

  • Eledon Pharmaceuticals, Inc. employs 33 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ELDN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELDNEledon Pharmaceuticals, Inc.$150.3M29
BBOTBridgebio Oncology Therapeutics, Inc.$145.1M22
PALIPalisade Bio, Inc.$146.4M19
PRQRProQR Therapeutics NV$146.8M47
STROSutro Biopharma, Inc.$140.9M56
ORMPOramed Pharmaceuticals, Inc.$148.5M66
ABEOAbeona Therapeutics, Inc.$138.1M53

Take a look at ELDN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Eledon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ELDN

What is the ELDN stock price forecast for 2026-2027?

The median 12-month analyst price target for Eledon Pharmaceuticals, Inc. is $8, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELDN stock a buy right now?

Of the 6 analysts covering Eledon Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eledon Pharmaceuticals, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELDN?

As at 21 Nov 2026, Eledon Pharmaceuticals, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (49 of 100).

Will ELDN stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $8, and Ticker Nerd's factor model ranks Eledon Pharmaceuticals, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELDN stock forecast for 2030?

No analyst covering Eledon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.

How has ELDN stock performed over the past year?

Eledon Pharmaceuticals, Inc. returned +28.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eledon Pharmaceuticals, Inc. do?

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection.

Company

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection. Eledon is currently advancing research programs in kidney transplantation, islet cell transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Its work centers on therapies intended to protect transplanted organs, reduce rejection risk, and address serious diseases with limited treatment options. Headquartered in Irvine, California, Eledon Pharmaceuticals operates as a focused drug development company within the broader biotechnology and immunology market.

CEO Dr. David-Alexandre C. Gros M.D., Ph.D. · 33 employees · United States · https://eledon.com